Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-23T06:45:21.641Z Has data issue: false hasContentIssue false

Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child

Published online by Cambridge University Press:  09 February 2024

Jeffrey R. Strawn  and
Stephen M. Stahl
Jeffrey R. Strawn
Affiliation:
University of Cincinnati, Ohio
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

How does an ∏2A receptor agonist improve attention?

Type
Chapter
Information
Case Studies: Stahl's Essential Psychopharmacology
Children and Adolescents
 , pp. 95 - 118
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Barkley, R. A., DuPaul, G. J., McMurray, M. B. Attention deficit disorder with and without hyperactivity: clinical response to three dose levels of methylphenidate. Pediatrics 1991; 87(4): 519–31. https://doi.org/10.1542/peds.87.4.519Google Scholar
Bousquet, P., Hudson, A., García-Sevilla, J. A., Li, J. X. Imidazoline receptor system: the past, the present, and the future. Pharmacol Rev 2020; 72(1): 50–79. https://doi.org/10.1124/pr.118.016311Google Scholar
Cortese, S., Adamo, N., Del Giovane, C., et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry 2018; 5(9): 519–31. https://doi.org/10.1016/S2215-0366(18)30269-4Google Scholar
Cortese, S., Holtmann, M., Banaschewski, T., et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry Allied Discip 2013; 54(3): 227–46. https://doi.org/10.1111/jcpp.12036Google Scholar
Farhat, L. C., Flores, J. M., Behling, E., et al. The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis. Molec Psychiatry 2022: 27(3): 1562–72. https://doi.org/10.1038/s41380-021-01391-9Google Scholar
Hammerness, P. G., Perrin, J. M., Shelley-Abrahamson, R., Wilens, T. E. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry 2011; 50(10): 978–90. https://doi.org/10.1016/j.jaac.2011.07.018Google Scholar
Martin, P., Satin, L., Vince, B. D., et al. Pharmacokinetics and pharmacodynamics of guanfacine extended release in adolescents aged 13–17 years with attention-deficit/hyperactivity disorder. Clin Pharmacol Drug Devel 2014; 3(4): 252–61. https://doi.org/10.1002/cpdd.124Google ScholarPubMed
Ming, X., Mulvey, M., Mohanty, S., Patel, V. Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders. Adolesc Health Med Ther 2011; 2: 105–12. https://doi.org/10.2147/AHMT.S15672Google Scholar
Newcorn, J. H., Stein, M. A., Cooper, K. M. Dose-response characteristics in adolescents with attention-deficit/hyperactivity disorder treated with OROS methylphenidate in a 4-week, open-label, dose-titration study. J Child Adolesc Psychopharmacol 2010; 20(3): 187–96. https://doi.org/10.1089/cap.2009.0102Google Scholar
Sallee, F. R., Kollins, S. H., Wigal, T. L. Efficacy of guanfacine extended release in the treatment of combined and inattentive only subtypes of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2012; 22(3): 206–14. https://doi.org/10.1089/cap.2010.0135Google Scholar
Sallee, F. R., McGough, J., Wigal, T., et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009; 48(2): 155–65. https://doi.org/10.1097/CHI.0b013e318191769eGoogle Scholar
Sayer, G. R., McGough, J. J., Levitt, J., et al. Acute and long-term cardiovascular effects of stimulant, guanfacine, and combination therapy for attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2016; 26(10): 882–88. https://doi.org/10.1089/cap.2015.0264Google Scholar
Stein, M. A., Sarampote, C. S., Waldman, I. D., et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2003; 112(5): e404. https://doi.org/10.1542/peds.112.5.e404Google Scholar
Strawn, J. R., Compton, S. N., Robertson, B., et al. Extended release guanfacine in pediatric anxiety disorders: a pilot, randomized, placebo-controlled trial. J Child Adolesc Psychopharmacol 2017; 27 (1): 29–37. https://doi.org/10.1089/cap.2016.0132Google Scholar
Strawn, J. R., Prakash, A., Zhang, Q., et al. A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder. J Am Acad Child Adolesc Psychiatry 2015; 54(4): 283–93. https://doi.org/10.1016/j.jaac.2015.01.008Google Scholar
Stuckelman, Z. D., Mulqueen, J. M., Ferracioli-Oda, E., et al. Risk of irritability with psychostimulant treatment in children with ADHD: a meta-analysis. J Clin Psychiatry 2017; 78(6): e648–55. https://doi.org/10.4088/JCP.15r10601Google Scholar
Wilens, T. E., Bukstein, O., Brams, M., et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2012; 51(1): 74–85. https://doi.org/10.1016/j.jaac.2011.10.012Google Scholar
Wilens, T. E., Robertson, B., Sikirica, V., et al. A randomized, placebo-controlled trial of guanfacine extended release in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2015; 54(11): 916–25. https://doi.org/10.1016/j.jaac.2015.08.016Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×